Comments on: Good News For Roche, Excellent News For Immunogen

By: Ohad Hammer

Ohad Hammer — Fri, 27 Mar 2009 14:18:16 +0000

Looking at T-DM1’s overall potential, IMGN isn’t too expensive but it certainly isn’t cheap. Now it all depends on ASCO. If Genentech publishes good data from its 2nd+ line trial IMGN could go higher but if not, a correction will have to occur. Until then, it’s impossible to predict the stock behavior imo. I have to admit that we are considering selling some IMGN in the biotech portfolio.
It’s funny you mention SGEN because it also shows that these companies, no matter how promising can get pretty volatile and it’s up to us to take advantage of this volatility.

ohad

By: sam

sam — Fri, 27 Mar 2009 02:49:18 +0000

I should have bought imgn when it was close to 5 dollars just a few weeks ago and now is up 40% since then.
How much limited upside is there? What is your price target? When does imgn become too expensive?

I bought sgen when you recommended it and I am up nearly 40% since you recommended about 3 weeks ago!

By: Ohad Hammer

Ohad Hammer — Thu, 19 Mar 2009 12:11:47 +0000

thanks

that’s a tough question. Not sure I can answer this one….

ohad

By: sam

sam — Thu, 19 Mar 2009 03:30:25 +0000

I have so far bought sgen and crx….wish I had bought imgn when I had the chance.

What would you say are the 3 best buys in your portfolio?

I really like reading your objective opinions.